 |
|
|
| |
PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY:
RESULTS FROM THE PROSPECTIVE DARING-B STUDY
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
M Papatheodoridi1, E Hadziyannis2, F Berby3, E Rigopoulou4, K Zachou4, B Testoni3, A Lyberopoulou4, N Gatselis4, J Vlachogiannakos1, S Manolakopoulos1,2, GN Dalekos4, F Zoulim3, GV Papatheodoridis1.
1Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 2Department of Medicine and Research Laboratory of Internal Medicine, Thessaly University Medical School, Larissa, Greece; 3Department of Hepatology, Hospices Civils de Lyon, CRCL-INSERM U1052, Lyon University, Lyon, France;42nd Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece.
|
| |
|
|
|
|
|
